Skip to Content

Tag: Insulin


Also Noted

WellDoc receives FDA clearance for BlueStar insulin calculator

August 31, 2023HME News Staff

COLUMBIA, Md. – WellDoc, a provider of digital health chronic care solutions, has received 510(k) clearance from the Food and Drug Administration for its BlueStar diabetes solution. BlueStar provides bolus insulin dose recommendations based on the most recent glucose reading and rate of change from a compatible continuous glucose monitoring (CGM) device. This feature enhances BlueStar’s existing digital coaching capabilities, which guide dietary and lifestyle decisions and assist individuals...

BlueStar, Diabetes, Insulin, Welldoc


Read Full Articlered right arrow icon

Also Noted

Tandem study shows great improvement for high A1c

April 18, 2023HME News Staff

SAN DIEGO – Tandem Diabetes Care, has published the result of a meta-analysis of three randomized controlled trials of its Control-IQ advanced hybrid closed-loop technology. The results, published in Diabetes Technology & Therapeutics demonstrate the positive clinical impact of the system’s automatic correction bolusing on glucose control across a wide range of ages and demographics of people with Type 1 diabetes. People with the highest baseline blood sugar levels experienced the greatest...

Insulin, Insulin pumps, Tandem Diabetes Care


Read Full Articlered right arrow icon

Also Noted

Glooko partners with insulin-dosing platform

April 14, 2023HME News Staff

PALO ALTO, Calif. – Glooko, Inc. has entered into a partnership with Hedia, integrating its insulin dosing technology into Glooko’s diabetes management platforms for healthcare providers and people with diabetes. “We are very pleased to partner with Hedia to offer this algorithm-driven innovation for personalized healthcare for diabetes patients and their healthcare teams,” said Russ Johannesson, CEO of Glooko. “The robust clinical data supporting Hedia’s efficacy...

Diabetes, Glooko, Insulin


Read Full Articlered right arrow icon

News

In brief: F&P’s expectations, insulin affordability, Power 500 list

January 27, 2023HME News Staff

AUCKLAND, New Zealand – Fisher & Paykel Healthcare expects full year operating revenue for the 2023 financial year to be within the range of about $1.55 billion to $1.6 billion, the company announced on Jan. 19.  In F&P’s Homecare Product Group, sales of obstructive sleep apnea masks have remained strong, said Lewis Gradon, managing director and CEO.  “Our mask sales growth rate is currently tracking above that of our first half as global supply of CPAP hardware...

AdaptHealth, CPAP, Dr. Rory Cooper, Fisher & Paykel Healthcare, Home Medical Equipment (HME), Insulin, ResMed, U.S. Rehab


Read Full Articlered right arrow icon

News

Report: Insulin cap to generate millions in savings for Medicare beneficiaries 

January 26, 2023HME News Staff

WASHINGTON – If the Inflation Reduction Act’s provision capping the cost of insulin at $35 for a month’s supply had been in place in 2020, 1.5 million Medicare beneficiaries across the country would have saved an average of $500, according to a new report from the U.S. Department of Health and Human Services.  Starting July 1, under Medicare Part B, beneficiary cost sharing will be limited to $35 for a month’s supply of insulin, which will result in an estimated $27...

Diabetes, Insulin, Medicare


Read Full Articlered right arrow icon

Also Noted

Ascensia supports Spare a Rose campaign

February 11, 2021HME News Staff

BASEL, Switzerland – Ascensia Diabetes Care is supporting the 2021 Spare a Rose campaign, which encourages people to donate the $5 cost of each rose they would have given someone on Valentine’s Day to Life for a Child. The organization provides lifesaving diabetes supplies and insulin to children in countries such as Mauritania, Jamaica and India. “While people around the world will be buying flowers and cards for their loved on this Valentine’s Day, many of...

Diabetes, Insulin, Spare a Rose Campaign


Read Full Articlered right arrow icon

News

Medicare Advantage: CMS touts reduced premiums, increased access

September 25, 2020HME News Staff

WASHINGTON - The Medicare Advantage average monthly plan premium is expected to decrease 11% to $21 in 2021, CMS has announced. Since 2017, the average monthly plan premium has decreased 34.2%, according to the agency, saving beneficiaries nearly $1.5 billion in costs. “This is the lowest that the average monthly premium for a Medicare Advantage plan has been since 2007,” CMS state. “In some states, including Alabama, Nevada, Michigan and Kentucky, beneficiaries will see average...

Insulin, Medicare Advantage, Premiums, Telehealth


Read Full Articlered right arrow icon

Specialty Providers

Medtronic seeks to integrate CGM, smart pen

September 25, 2020Theresa Flaherty, Managing Editor

DUBLIN, Ireland - Although Medtronic is a leader in insulin pump technology, the majority of people with diabetes who use insulin still opt for injections—that's why the company wants to “close the loop” for those patients. In August, Medtronic announced it had acquired Companion Medical, the manufacturer of?InPen, a smart insulin pen system paired with an integrated diabetes management app that helps with insulin dosing and tracking. “It became apparent...

Continuous Glucose Monitor (CGM), Insulin, Medtronic, smart pen, Technology


Read Full Articlered right arrow icon

Also Noted

Plans buy into insulin savings model

May 27, 2020HME News Staff

WASHINGTON - More than 1,750 standalone Medicare Part D prescription drug plans and Medicare Advantage plans with prescription drug coverage have applied to offer lower insulin costs through the Part D Senior Savings Model for 2021. Across the nation, participating enhanced Part D prescription drug plans will provide Medicare beneficiaries access to a broad set of insulins at a maximum $35 co-pay for a month's supply from the beginning of the year through the Part D coverage gap. Based on CMS's estimates,...

Diabetes, Insulin, savings


Read Full Articlered right arrow icon

Also Noted

New law caps insulin co-pays at $100

May 28, 2019HME News Staff

DENVER - Colorado Gov. Jared Polis has signed a new law that caps co-payments for prescription insulin to $100 a month for insured patients, regardless of the amount or type of drug needed. The law also directs the state's attorney general to investigate pricing of insulin drugs and determine whether or not additional consumer protections are needed. Colorado is the first state to enact such a law, according to news reports. Almost 20,000 Coloradans are diagnosed with diabetes each year and as of...

Cost, Insulin


Read Full Articlered right arrow icon